

Special Issue

Pediatric Brain Tumor

Message from the Guest Editors

This special issue will present advanced clinical and research articles and high quality review-papers focusing on the latest advances in the treatment of pediatric malignant brain tumors, which may include targeted therapy and immunotherapy. We request research scientists to submit the results of not only molecular-based but translational investigations of malignant pediatric brain tumors directing for prospective clinical applications. We encourage clinicians to submit their articles describing innovative diagnostic (e.g., liquid biopsy; molecular classification), and therapeutic approaches and protocols with their results. Surgeons are encouraged to submit their experience of minimally invasive surgery and regional therapy such as convection enhanced delivery, radiation therapy and thermo-ablation in order to contribute to the care of prospective pediatric brain tumors. Comprehensive up-to-date reviews to these topics are also encouraged in order to summarize and understand the current status and future directions.

Guest Editors

Prof. Dr. Tadanori Tomita

Dr. Guifa Xi

Prof. Dr. Stewart Goldman

Deadline for manuscript submissions

closed (31 January 2020)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/23841

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)